See more : Bluejay Diagnostics, Inc. (BJDX) Income Statement Analysis – Financial Results
Complete financial analysis of IRadimed Corporation (IRMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IRadimed Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- SVB Financial Group (SIVB) Income Statement Analysis – Financial Results
- Precomp Solutions AB (publ) (PCOM-B.ST) Income Statement Analysis – Financial Results
- Record plc (REC.L) Income Statement Analysis – Financial Results
- NH Foods Ltd. (NIPMY) Income Statement Analysis – Financial Results
- A.L.A. società per azioni (ALA.MI) Income Statement Analysis – Financial Results
IRadimed Corporation (IRMD)
About IRadimed Corporation
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.56M | 53.30M | 41.81M | 31.72M | 38.52M | 30.44M | 23.08M | 32.50M | 31.59M | 15.65M | 11.34M | 7.69M |
| Cost of Revenue | 15.40M | 12.02M | 9.76M | 8.14M | 8.82M | 7.21M | 5.57M | 6.15M | 5.84M | 3.40M | 2.85M | 2.13M |
| Gross Profit | 50.16M | 41.28M | 32.05M | 23.57M | 29.70M | 23.23M | 17.51M | 26.34M | 25.75M | 12.25M | 8.49M | 5.56M |
| Gross Profit Ratio | 76.50% | 77.45% | 76.65% | 74.33% | 77.11% | 76.31% | 75.87% | 81.06% | 81.51% | 78.25% | 74.84% | 72.34% |
| Research & Development | 2.86M | 2.28M | 1.91M | 1.90M | 1.43M | 1.52M | 1.72M | 1.35M | 1.76M | 1.07M | 1.01M | 654.07K |
| General & Administrative | 15.12M | 10.70M | 9.77M | 12.27M | 10.45M | 8.71M | 9.00M | 8.80M | 7.77M | 4.82M | 2.39M | 1.55M |
| Selling & Marketing | 12.14M | 12.68M | 10.56M | 10.16M | 9.17M | 7.00M | 5.50M | 5.28M | 4.71M | 3.30M | 2.30M | 1.93M |
| SG&A | 27.26M | 23.38M | 20.33M | 22.43M | 19.62M | 15.71M | 14.50M | 14.07M | 12.48M | 8.11M | 4.69M | 3.48M |
| Other Expenses | 0.00 | 553.10K | 18.61K | 139.21K | 395.91K | 193.54K | 111.38K | 32.68K | 121.39K | -48.55K | -3.46K | 7.42K |
| Operating Expenses | 30.12M | 25.65M | 22.23M | 24.33M | 21.05M | 17.22M | 16.23M | 15.42M | 14.24M | 9.18M | 5.70M | 4.13M |
| Cost & Expenses | 45.53M | 37.68M | 32.00M | 32.47M | 29.87M | 24.44M | 21.80M | 21.58M | 20.08M | 12.59M | 8.55M | 6.26M |
| Interest Income | 1.86M | 581.85K | 34.81K | 132.19K | 388.80K | 238.11K | 122.58K | 126.42K | 148.91K | 5.70K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 581.85K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 765.18K | 670.67K | 634.01K | 603.60K | 591.18K | 559.73K | 445.27K | 248.30K | 223.94K | 149.06K | 139.04K | 106.28K |
| EBITDA | 20.80M | 16.30M | 11.22M | 582.73K | 9.89M | 7.11M | 2.59M | 11.17M | 11.51M | 3.21M | 2.93M | 1.53M |
| EBITDA Ratio | 31.73% | 29.32% | 26.84% | 1.84% | 25.68% | 23.35% | 11.24% | 34.37% | 37.15% | 20.54% | 25.80% | 19.92% |
| Operating Income | 20.04M | 15.63M | 9.82M | -756.09K | 8.65M | 6.00M | 1.29M | 10.92M | 11.51M | 3.07M | 2.79M | 1.42M |
| Operating Income Ratio | 30.56% | 29.32% | 23.48% | -2.38% | 22.45% | 19.72% | 5.57% | 33.60% | 36.44% | 19.59% | 24.58% | 18.54% |
| Total Other Income/Expenses | 1.70M | 553.10K | 18.61K | 139.21K | 395.91K | 193.54K | 111.38K | 32.68K | 121.39K | -48.55K | -3.46K | 7.42K |
| Income Before Tax | 21.74M | 16.18M | 9.84M | -616.88K | 9.04M | 6.20M | 1.40M | 10.95M | 11.63M | 3.02M | 2.78M | 1.43M |
| Income Before Tax Ratio | 33.16% | 30.36% | 23.52% | -1.94% | 23.48% | 20.36% | 6.05% | 33.70% | 36.83% | 19.28% | 24.55% | 18.63% |
| Income Tax Expense | 4.55M | 3.35M | 510.82K | -1.99M | -587.64K | -106.14K | 896.62K | 3.74M | 4.10M | 966.98K | 846.88K | 465.98K |
| Net Income | 17.19M | 12.83M | 9.33M | 1.37M | 9.63M | 6.30M | 499.76K | 7.21M | 7.53M | 2.05M | 1.94M | 966.09K |
| Net Income Ratio | 26.22% | 24.07% | 22.30% | 4.32% | 25.00% | 20.71% | 2.17% | 22.20% | 23.83% | 13.10% | 17.08% | 12.57% |
| EPS | 1.36 | 1.02 | 0.76 | 0.11 | 0.85 | 0.52 | 0.05 | 0.67 | 0.68 | 0.23 | 0.19 | 0.09 |
| EPS Diluted | 1.35 | 1.02 | 0.74 | 0.11 | 0.78 | 0.52 | 0.04 | 0.60 | 0.60 | 0.20 | 0.19 | 0.09 |
| Weighted Avg Shares Out | 12.60M | 12.56M | 12.35M | 12.12M | 11.28M | 12.11M | 10.64M | 10.82M | 11.00M | 8.74M | 10.42M | 10.42M |
| Weighted Avg Shares Out (Dil) | 12.72M | 12.64M | 12.59M | 12.44M | 12.28M | 12.11M | 11.72M | 11.99M | 12.56M | 10.22M | 10.42M | 10.42M |
IRADIMED CORPORATION Announces Second Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share
WINTER SPRINGS, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three and six months ended June 30, 2024. The Company is a leader in the development of innovative...
IRADIMED CORPORATION to Hold 2024 Second Quarter Financial Results Conference Call on August 1st
Winter Springs, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 second quarter financial results before the market opens on Thursday, August 1, 2024. Iradimed management will host a conference...
IRADIMED CORPORATION Announces Uplisting to The Nasdaq Global Market
WINTER SPRINGS, Fla., June 07, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today its common stock will uplist and commence trading on the Nasdaq Global...
IRADIMED CORPORATION (IRMD) Q1 2024 Earnings Call Transcript
IRADIMED CORPORATION (NASDAQ:IRMD ) Q1 2024 Results Conference Call May 2, 2024 11:00 AM ET Company Participants Roger Susi - President and Chief Executive Officer Jack Glenn - Chief Financial Officer Conference Call Participants Jason Wittes - ROTH Capital Partners...
IRADIMED CORPORATION Announces First Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share
WINTER SPRINGS, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three months ended March 31, 2024. The Company is a leader in the development of innovative magnetic resonance...
IRADIMED CORPORATION to Hold 2024 First Quarter Financial Results Conference Call on May 2nd
WINTER SPRINGS, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 first quarter financial results before the market opens on Thursday, May 2, 2024. Iradimed management will host a...
IRADIMED CORPORATION To Participate at the 36th Annual Roth Conference
WINTER SPRINGS, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that Roger Susi, the Company's President and Chief Executive Officer, will present at the 36th Annual Roth Conference in Laguna Niguel, CA.
IRadimed Corporation (IRMD) Q4 2023 Earnings Call Transcript
IRadimed Corporation (IRMD) Q4 2023 Earnings Call Transcript
IRADIMED CORPORATION Announces Fourth Quarter of 2023 and Full Year of 2023 Financial Results
WINTER SPRINGS, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three months and year ended December 31, 2023. The Company is a leader in the development of innovative magnetic...
IRADIMED CORPORATION to Hold 2023 Fourth Quarter Financial Results Conference Call on February 8th.
WINTER SPRINGS, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2023 fourth quarter financial results before the market opens on Thursday, February 8, 2024. Iradimed management will host a conference...
Source: https://incomestatements.info
Category: Stock Reports